Efficacy of anti-PD1/PD-L1 immunotherapy in non–small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status.

• DOI: 10.1200/jco.2022.40.16_suppl.2509
• Publication Date: 2022-06-06T16:03:57Z
• Authors: Jerome Galon; Frederic Bibeau; Laurent Greillier; Jean David Fumet; Alis Ilie; Florence Monville; Caroline Laugé; Aurelie Catteau; Isabelle Boquet; Amine Majdi; Youssef Oulkhouir; Nicolas Brandone; Julien Adam; Thomas Sbarrato; Alboukadel Kassam...; Jacques Fieschi; Stephane Garcia; Anne Laure Lepage; Pascale Tomasini; François Ghiringh...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

2509 Background: Anti-PD1 and PD-L1 antibodies (mAb) are immune checkpoint inhibitors (ICIs) to treat patients with metastatic non–small cell lung cancer (NSCLC). Unfortunately, only a handful of respond ICIs. Methods: A cohort NSCLC (n=133) treated anti-PD1 or anti-PD-L1 mAb in two independent care centers was evaluated. An 132 from another hospital used as validation. Immunoscore IC, an vitro diagnostic test (CE-IVD), on routine single FFPE slide, duplex immunohistochemistry CD8 staining quantified using digital pathology. Quantitative spatial parameters related location, number, proximity, clustering were analyzed. IC–based model discriminated into 2 categories 3 categories. Results: Anti–PD-L1 clone (HDX3) had similar characteristics other anti–PD-L1 clones (22C3, SP263) mean overall agreement above 95%. Intra- inter-laboratory concordances for classifying at 1% cut-off according 100% 94%, respectively. Routine laboratory evaluation expression showed quantification 92% 97% 50% cut-offs, Using univariate Cox after FDR correction, 5 pathological dichotomized variables significantly associated PFS (all p < 0.0001). These included: free PD-L1, clusters, cells proximity cells, cells. Similar results found analysis continuous 0.003) cohorts patients. multivariate IC classification improved the discriminating power prognostic model, which included clinical pathologist assessment. In categories, risk score both patients’ (p 0.0001) OS training validation (PFS: = 0.0047, OS: Further increased hazard ratios when stratifying IC. At 6 months, rates 10% versus 60% 20% 62% high-risk low-risk score, All (100%) relapsed less than 18 contrast 34% 33% who did not relapse more 36 months cohorts, Conclusions: data underline that is potent tool predict efficacy ICIs NSCLC. characterized resistant